Fresh analysis suggests that patients who discontinue new weight-loss injections like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who stop traditional lifestyle programs.
Published data in a major health publication demonstrates that while overweight individuals can lose a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such medications need to be cognizant of the potential of fast weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a return to original mass in about 18 months.
Comparing Treatments
The research, which examined 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with conventional dieting.
Researchers point out that individuals who shed pounds through lifestyle changes alone generally have a less rapid weight regain—around 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Experts suggest the mode of action of the drugs is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, given the significant potential of relapse, the therapy should be considered ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "underscore the persistent nature of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
People who have discontinued the medication report a sudden resurgence of cravings.
"It felt as if something that goes on and you're instantly starving," said one woman.
This challenge is exacerbated if users have not established sustainable dietary or behavioural changes during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is higher among women compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural changes.
